In The Search For New Drugs, Diverging Roads For Microdosing
Subtherapeutic doses in drug development tests have shown important—but unanticipated—advantages
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
January 21, 2013 Cover
Volume 91, Issue 3
Subtherapeutic doses in drug development tests have shown important—but unanticipated—advantages
Cover image:
Credit:
Drug Development
Instrument Maker Wyatt Charts Its Own Course
California firm values independence as it flaunts its technical competence
-
The Autograph Collector
Tetsuo Nozoe’s newly published collection of chemists’ signatures and structures showcases 41 years of vital science
-
Survey Exposes Lab Safety Gaps
Researchers reveal troubling practices and perceptions in laboratories
-
Drugmaker Questcor Buys Its Chemical Supplier, BioVectra
Unusual deal is a diversification move for growing California firm
ADVERTISEMENT
Science Concentrates
Solar Power Generates Methanol From CO2
Hybrid copper oxide nanorods convert sunlight to photocurrent for driving electrochemical transformations
